Nagasaki International University, Sasebo, Japan.
Acta Haematol. 2010;124(4):218-24. doi: 10.1159/000321518. Epub 2010 Nov 13.
Thrombosis is characterized by congenital and acquired procatarxis. Nattokinase inhibits thrombus formation in vitro. However, in vivo evaluation of the therapeutic efficacy of nattokinase against thrombosis remains to be conducted. Subcutaneous nattokinase injections of 1 or 2 mg/ml were administered to the tails of rats. Subsequently, κ-carrageenan was intravenously administered to the tails at 12 h after nattokinase injections. The mean length of the infarcted regions in the tails of rats was significantly shorter in rats administered 2 mg/ml of nattokinase than those in control rats. Nattokinase exhibited significant prophylactic antithrombotic effects. Previously, the in vitro efficacy of nattokinase against thrombosis had been reported; now our study has revealed the in vivo efficacy of nattokinase against thrombosis.
血栓形成的特点是先天和后天的促凝血作用。纳豆激酶抑制体外血栓形成。然而,纳豆激酶对血栓形成的治疗效果的体内评估仍有待进行。将 1 或 2mg/ml 的纳豆激酶皮下注射到大鼠的尾部。随后,在纳豆激酶注射后 12 小时向大鼠尾部静脉内给予 κ-卡拉胶。给予 2mg/ml 纳豆激酶的大鼠尾部梗死区域的平均长度明显短于对照组大鼠。纳豆激酶表现出显著的预防性抗血栓作用。以前已经报道了纳豆激酶在体外抗血栓形成的功效;现在我们的研究揭示了纳豆激酶在体内抗血栓形成的功效。